ClinicalTrials.gg
Active, not recruitingNCT06617793Updated Sep 2, 2026

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

A Phase 1/2 interventional study of rapcabtagene autoleucel (YTB323) in Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 18 sites in 6 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Multiple Sclerosis by Novartis — 9 open to participants now, 24 under way, 6 of them phase 3. Multiple Sclerosis · Novartis.

Planned enrollment
53rd of 64
28 · median 147
Started
2025
with 4 others
Phase 1/2
3 of 106
none open now
Primary completion
2030-08
later than 20 of 23 live
Registered
92nd of 106
by date

Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 53rd largest by planned enrollment of the 64 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 1/2, reaches primary completion later than 20 of the 23 other live ones, and was the 92nd registered.

Multiple Sclerosis

3,272 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

9 of the 106 studies in Multiple Sclerosis by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Multiple Sclerosis by Novartis, or all of them as a file.
02

Study summary

This is an open-label, multi-center, non-confirmatory study to assess the safety, efficacy, and cellular kinetics of YTB323 in approximately 28 participants with Relapsing Multiple Sclerosis (RMS) with breakthrough disease activity during previous treatment with a highly efficacious therapy (BD-HET). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.

Read the detailed description

All participants in this study will receive YTB323. Both the participant and the study doctor will know the participant is getting YTB323. Participants will be given one dose of YTB323. Different groups of participants may receive a higher dose of YTB323, if proven to be safe for every participant at the lower dose. Participants are in this study for 2 years and will be followed for an additional 13 years in a long-term follow up study. The main question this trial is designed to answer: Is YTB323 treatment safe for participants with relapsing MS?

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

Keywords

  • Chimeric Antigen Receptor T cells
  • CAR-T
  • YTB323
  • Multiple Sclerosis
  • MS
  • Relapsing Multiple Sclerosis
  • RMS
  • breakthrough disease activity during previous treatment with a highly efficacious therapy
  • BD-HET
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed , and able to communicate well with the investigator and comply with the requirements of the study
  • Adequate renal, hepatic, cardiac, hematological, and pulmonary function
  • Male or female participants, ≥18 years to ≤60 years at screening, with diagnosis of RMS according to the 2017 McDonald diagnostic criteria Evidence of recent (i.e. within 1 year) breakthrough disease activity while at least 6 months on a highly efficacious therapy (any of the following): rituximab (Rituxan®), ocrelizumab (Ocrevus®), natalizumab (Tysabri®), ofatumumab (Kesimpta®), ublituximab (Briumvi®) or evidence of breakthrough disease activity within 2 years after the latest alemtuzumab infusion (Lemtrada®).

Evidence of breakthrough disease activity is defined as one or more of the following:

  1. Confirmed Clinical MS relapse
  2. Persistent radiological activity defined by one of the following:

    • ≥2 T1 gadolinium-enhancing lesions on a single MRI scan
    • ≥1 T1 gadolinium-enhancing lesions on two or more separate MRI scans
    • ≥2 new T2 lesions compared to a previous scan within a period ≤1 year

      • Ambulatory patients (EDSS of 3 to 6 points, inclusive assessed outside of relapse)
      • Disease duration less than 15 years
      • Participants must receive or be current on all recommended vaccinations according to institutional, local, or global guidelines for patients at least 6-weeks prior to lymphodepletion

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of primary progressive multiple sclerosis (PPMS) according to the 2017 revision of the McDonald diagnostic criteria at screening
  • History of or current CNS disease (e.g. stroke, traumatic brain or spinal injury, history or presence of myelopathy) or neurological disorders which may mimic MS or ICANS at screening
  • Evidence of clinically significant cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, (NYHA) Class III/IV left ventricular failure, arrhythmia and uncontrolled hypertension within 6 months prior to screening), neurological disorders other than MS (including seizure disorders even when well controlled), psychiatric, pulmonary (including, history of or active severe respiratory disease, including , interstitial lung disease or pulmonary fibrosis), renal, hepatic, endocrine, metabolic (e.g. severe hypoproteinemia due to nephrotic syndrome), hematological disorders or gastrointestinal disease that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant, prior to screening
  • Have donated blood or experienced a loss of blood > 400 mL within 3 months prior screening, or longer if required by local regulations
  • Any prior stem cell therapy or organ transplantation or gene therapy
  • Any to LP, including but not limited to:

    • Known or suspected structural abnormality of the lumbar spine that, in the opinion of the Investigator, may interfere with the performance of the LP, or increase the risk of the procedure for the participant
    • Presence of risk for increased or uncontrolled bleeding including, but not limited to, vascular abnormalities or neoplasms at or near the LP site, disorders of the coagulation cascade, function, or platelet count
    • Participants on anticoagulants (e.g., warfarin) or antiplatelets [except for low-dose aspirin (100 mg/day or lower) and low-dose ibuprofen (600 mg/day or lower) which are allowable], are not eligible to participate
  • Participants not willing or able to take MRI scans as per protocol. Unable to undergo MRI due to for example claustrophobia, or presents absolute contraindications to MRI (e.g., metallic implants, metallic foreign bodies, pacemaker, defibrillator)

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    YTB323 Cohort 1

    Participants will receive one dose of YTB323

    Biological: rapcabtagene autoleucel (YTB323)

  • Experimental
    YTB323 Cohort 2

    Participants will receive one dose of YTB323

    Biological: rapcabtagene autoleucel (YTB323)

  • Experimental
    YTB323 Cohort 3

    Participants will receive one dose of YTB323

    Biological: rapcabtagene autoleucel (YTB323)

  • Experimental
    YTB323 Cohort 4

    Participants will receive one dose of YTB323

    Biological: rapcabtagene autoleucel (YTB323)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Incidence of dose limiting toxicities (DLTs), AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs), laboratory parameters, neurological status and magnetic resonance (MRI) of the brain and spinal cord qualifying and reported as AEs.

    Time frame: Day 1 through Year 2

Secondary outcomes

  1. Measure of Disability: Expanded Disability Status Scale (EDSS).

    EDSS is used to measure the change in disability level in participants using a scale from 0 to 10. The higher the score, the greater the degree of disability.

    Time frame: Day 1 through Year 2

  2. Measure of Disability: Short Form Health Survey (SF-36 v2)

    The Short Form Health Survey (SF-36 v2) is a widely used and extensively studied instrument to measure health-related quality of life among healthy participants and participants with acute and chronic conditions. It consists of eight subscales that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS) also can be computed. The SF 36 has proven useful in monitoring general and specific populations, comparing the relative burden of different diseases, differentiating the health benefits produced by different treatments, and in screening individual participants.

    Time frame: Day 1 through Year 2

  3. Measure of Disability: Timed 25 Foot Walk (T25FW)

    The T25FW is a mobility test based on a timed walk of 25 feet that is administered by a trained administrator. The participant is directed to walk the clearly marked 25-foot distance as quickly as possible. Longer completion time corresponds with decreased mobility.

    Time frame: Day 1 through Year 2

  4. Measure of Disability: 9 Hole Peg Test (9HPT)

    The 9HPT is a finger dexterity test that is administered by a trained administrator. The participant is directed to put 9 pegs, one by one, onto and then off the holder board as quickly as possible starting with using only the dominant hand, and then repeated with the non-dominant hand. Longer completion times are associated with decreased finger dexterity.

    Time frame: Day 1 through Year 2

  5. Measure of Disability: Symbol Digit Modalities Test (SDMT)

    The SDMT is a timed cognition test administered by a trained administrator. The test assesses sustained attention, processing speed, visual scanning, and motor speed to determine cognitive impairment. Participants are given a coding key which contains abstract symbols that correspond to specific numbers. Participants are timed how quickly and accurately they are able to substitute the symbols for the numbers and is scored by the number of correctly coded items.

    Time frame: Day 1 through Year 2

  6. Measure of Disability: Fatigue Symptoms and Impacts Questionnaire - Relapsing Multiple Sclerosis (FSIQ-RMS)

    The FSIQ-RMS is a questionnaire to assess fatigue-related symptoms in patients with RMS. Participants will indicate the severity of fatigue experienced for each question that examines different aspects of fatigue.

    Time frame: Day 1 through Year 2

  7. Number of new and enlarging T2 lesions and Gd-enhancing T1 Lesions

    Measured in the brain by Magnetic Residence Imaging (MRI)

    Time frame: Day 1 through Year 2

  8. Plasma Pharmacokinetics (PK) of YTB323 - CMAX

    Measured by Cmax - The maximum plasma concentration of YTB323

    Time frame: Day 1 through Year 2

  9. Plasma Pharmacokinetics (PK) of YTB323 - AUC

    Measured by AUC - Area under the curve of YTB323

    Time frame: Day 1 through Year 2

  10. Plasma Pharmacokinetics (PK) of YTB323 - Tmax

    Measured by Tmax - Time to Reach the Maximum Concentration After Drug Administration of YTB323

    Time frame: Day 1 through Year 2

  11. Plasma Pharmacokinetics (PK) of YTB323 - Clast

    Clast is defined as the Last observed (quantifiable) plasma concentration (Clast)

    Time frame: Day 1 through Year 2

  12. Plasma Pharmacokinetics (PK) of YTB323 - Tlast

    Tlast is defined as Time of Last Measurable Concentration

    Time frame: Day 1 through Year 2

  13. Safety data including dose limiting toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs) from each dose level

    Safety data from each dose level will be used to assess safe dose-level(s) to be continued in phase 2 and later clinical studies

    Time frame: Day 1 through Year 2

  14. Humoral Immunogenicity of YTB323

    Incidence and prevalence of pre-existing and treatment induced humoral immunogenicity of YTB323

    Time frame: Day 1 through Year 2

  15. Cellular Immunogenicity of YTB323

    Incidence and prevalence of pre-existing and treatment induced cellular immunogenicity of YTB323

    Time frame: Day 1 through Year 2

07

Study locations

18 sites
  • Novartis Investigative Site
    Darlinghurst, New South Wales 2010, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
  • Novartis Investigative Site
    Montpellier, 34090, France
  • Novartis Investigative Site
    Nancy, 54035, France
  • Novartis Investigative Site
    Rennes, 35033, France
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Milan, MI 20132, Italy
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Córdoba, 14004, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Lausanne, 1011, Switzerland
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Aug 2030, 65 months after the start.

Of 33 phase 1/2 interventional studies under Multiple Sclerosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 89. This study's planned 65 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2024
First posted
Sep 27, 2024
StartActual
Feb 24, 2025
Primary completionEst.
Aug 7, 2030
CompletionEst.
Aug 7, 2030
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06617793
Responsible party
Sponsor
First posted
Sep 27, 2024
Start date
Feb 24, 2025
Primary completion
Aug 7, 2030 (estimated)
Completion
Aug 7, 2030 (estimated)
Last update
Sep 2, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rapcabtagene autoleucel

Start the discussion